The latest price target for Omega Therapeutics (NASDAQ:OMGA) was reported by Piper Sandler on November 15, 2024. The analyst firm set a price target for $4.00 expecting OMGA to rise to within 12 months (a possible 377.95% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Omega Therapeutics (NASDAQ:OMGA) was provided by Piper Sandler, and Omega Therapeutics maintained their overweight rating.

There is no last upgrade for Omega Therapeutics

There is no last downgrade for Omega Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Omega Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Omega Therapeutics was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest Omega Therapeutics (OMGA) rating was a maintained with a price target of $9.00 to $4.00. The current price Omega Therapeutics (OMGA) is trading at is $0.84, which is out of the analyst’s predicted range.